Oncotype Score Calculator & Risk Interpreter
Understand your breast cancer recurrence risk based on your Oncotype DX score.
Interpret Your Score
This oncotype score calculator provides an interpretation based on data from the landmark TAILORx and NSABP B-14 clinical trials for patients with ER-positive, HER2-negative, node-negative breast cancer treated with endocrine therapy.
What is an Oncotype Score Calculator?
An oncotype score calculator is not a tool for generating your score, but rather for interpreting it. The Oncotype DX Recurrence Score is a sophisticated genomic test performed on a tumor sample after a biopsy or surgery. It analyzes the activity of 21 specific genes within cancer cells to help predict the likelihood of breast cancer recurrence and, crucially, whether a patient will benefit from adding chemotherapy to their treatment plan. This tool is specifically for patients with early-stage, estrogen receptor-positive (ER+), HER2-negative breast cancer. A common misconception is that you can calculate your score at home; this is impossible as it requires lab analysis. This online oncotype score calculator helps you understand what your score means for your prognosis.
The Oncotype Score Formula and Mathematical Explanation
The actual formula to derive the Oncotype DX Recurrence Score (RS) from the 21 genes is a proprietary algorithm developed by Exact Sciences. It’s not a simple public formula. The test uses a technique called RT-PCR to measure the expression levels of 16 cancer-related genes and 5 reference genes. These genes fall into categories like proliferation, invasion, HER2, and estrogen. The raw expression data is fed into the algorithm, which weights them and produces a final score from 0 to 100. Our oncotype score calculator interprets this final score, rather than computing it.
The interpretation provided by this calculator is based on large clinical trials, most notably the TAILORx study, which defined risk groups based on the score.
| Variable | Meaning | Measurement | Significance |
|---|---|---|---|
| ER (Estrogen Receptor) | Indicates if cancer cells grow in response to estrogen. | IHC (Immunohistochemistry) | ER-positive cancers are candidates for endocrine therapy. |
| PR (Progesterone Receptor) | Indicates if cancer cells grow in response to progesterone. | IHC | Similar to ER, suggests hormone sensitivity. |
| HER2 | Human Epidermal growth factor Receptor 2 status. | IHC / FISH | Oncotype DX is for HER2-negative cancers. |
| Ki-67 | A marker for cellular proliferation (how fast cells are dividing). | IHC (%) | Higher Ki-67 levels are associated with higher recurrence scores. |
| Tumor Grade | How abnormal cancer cells look under a microscope (1-3). | Pathology Review | Higher grade tumors tend to have higher recurrence scores. |
Practical Examples (Real-World Use Cases)
Example 1: Postmenopausal Patient, Intermediate Score
A 55-year-old postmenopausal woman is diagnosed with node-negative, ER+, HER2- breast cancer. Her Oncotype DX score is 18. She inputs this into the oncotype score calculator. The result shows she is in an “Intermediate Risk” group, but based on the TAILORx trial data for postmenopausal women, her 9-year risk of distant recurrence is low (~7%) and chemotherapy is shown to provide no significant benefit over endocrine therapy alone. Her treatment plan will likely be endocrine therapy only.
Example 2: Premenopausal Patient, High-Intermediate Score
A 48-year-old premenopausal woman receives a score of 24. Using the oncotype score calculator, she sees she falls into the “Intermediate Risk” group. However, for premenopausal women with scores between 16-25, the TAILORx study showed a potential benefit from chemotherapy. Her estimated 9-year recurrence risk with endocrine therapy alone is around 12-14%, but adding chemotherapy could reduce that risk. This result prompts a detailed discussion with her oncologist about the pros and cons of adding chemotherapy to her treatment, a key function of using this oncotype score calculator for context.
How to Use This Oncotype Score Calculator
- Enter Your Score: Input the Recurrence Score (a number from 0 to 100) from your official Oncotype DX report.
- Enter Your Age: Provide your age at the time of diagnosis.
- Select Menopausal Status: Choose whether you were premenopausal or postmenopausal at diagnosis.
- Review Your Results: The calculator will instantly display your risk group, estimated recurrence rate, and a summary of chemotherapy benefit based on major clinical trials.
- Explore the Chart and Table: The dynamic chart and table provide visual context, showing where your score falls and how risk levels are categorized. Using an oncotype score calculator like this helps visualize the data.
- Discuss with Your Doctor: This tool is for informational purposes. Always discuss your results and treatment plan with your oncology team.
Key Factors That Affect Oncotype Score Results
- Tumor Grade: Higher-grade tumors (more aggressive-looking cells) tend to have higher scores.
- Proliferation Rate (Ki-67): A high Ki-67 percentage, indicating rapid cell division, strongly correlates with a higher Oncotype score.
- Estrogen Receptor (ER) Status: While all tested tumors are ER-positive, the strength of the ER signal can influence the score.
- Progesterone Receptor (PR) Status: PR-negative tumors are often associated with higher recurrence scores.
- Gene Expression Profile: The core of the test is the specific expression levels of the 16 cancer-related genes. High expression of proliferation genes and low expression of estrogen-related genes drive the score up.
- Patient Age and Menopausal Status: As seen in the TAILORx trial, age and menopausal status are critical for interpreting scores in the intermediate range (11-25) to determine chemotherapy benefit. Understanding these factors is why a detailed oncotype score calculator is so useful.
Frequently Asked Questions (FAQ)
No. This is an interpretive tool. The actual Oncotype DX score can only be determined by a laboratory analysis of your tumor tissue.
A high score (e.g., 26 or greater) indicates a higher risk of the cancer recurring in a distant part of the body and also suggests that the benefit of adding chemotherapy to endocrine therapy is likely to be significant.
The TAILORx trial was a landmark study that proved many women with early-stage, ER+, HER2-, node-negative breast cancer and an intermediate Oncotype score (11-25) could safely avoid chemotherapy without affecting their long-term outcomes.
No. It is specifically designed for patients with early-stage, HR-positive, HER2-negative breast cancer. It may also be used for some patients with 1-3 positive lymph nodes. See our page on understanding ER-positive cancer for more details.
No. MammaPrint is a different type of genomic test that analyzes 70 genes and classifies tumors as either high or low risk. The Oncotype DX test provides a score on a spectrum from 0 to 100.
A score of 25 is on the cusp. If you are postmenopausal, TAILORx data suggests no chemotherapy benefit. If you are premenopausal, there is a potential benefit that should be carefully discussed with your doctor. This oncotype score calculator helps frame that conversation.
The test has been validated in numerous large-scale clinical studies and is considered a reliable tool for predicting recurrence risk and chemotherapy benefit. Its findings are integrated into major oncology guidelines worldwide. For more on risk, explore our breast cancer recurrence risk calculator.
No. A low score means the risk of distant recurrence is very low, but it is not zero. It is a prognostic tool, not a guarantee. Following your prescribed endocrine therapy is crucial. Understanding the role of chemotherapy for breast cancer is important context.
Related Tools and Internal Resources
- Breast Cancer Staging Calculator: Determine the stage of your breast cancer based on tumor size, node status, and metastasis.
- Understanding ER-Positive Cancer: A deep dive into what it means to have hormone-receptor-positive breast cancer.
- HER2-Negative Breast Cancer Treatment: Learn about the standard treatments for this common type of breast cancer.
- Breast Cancer Recurrence Risk: Another tool to help you assess your overall risk of recurrence.
- Endocrine Therapy Explained: An overview of hormone therapies like Tamoxifen and Aromatase Inhibitors.
- What is My Prognosis?: An article helping patients understand prognosis after a cancer diagnosis.